123 related articles for article (PubMed ID: 3534700)
1. [Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].
Ryckelynck JP; Vergnaud M; Hurault de Ligny B; Allouche G; Malbruny B; Morel C
Pathol Biol (Paris); 1986 May; 34(5):328-31. PubMed ID: 3534700
[TBL] [Abstract][Full Text] [Related]
2. Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.
Sisterhen LL; Stowe CD; Farrar HC; Blaszak CK; Blaszak RT
Am J Kidney Dis; 2006 Mar; 47(3):503-8. PubMed ID: 16490630
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of peritonitis under continuous ambulatory peritoneal dialysis using intraperitoneal ceftazidime].
Ragnaud JM; Dupon M; Morlat P; Bezian MC; Wone C
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):681-4. PubMed ID: 2677930
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal vancomycin and ceftazidime in the treatment of CAPD peritonitis.
Gray HH; Goulding S; Eykyn SJ
Clin Nephrol; 1985 Feb; 23(2):81-4. PubMed ID: 3886227
[TBL] [Abstract][Full Text] [Related]
5. Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie.
Klaus G; Schaefer F; Müller-Wiefel D; Mehls O
Adv Perit Dial; 1995; 11():296-301. PubMed ID: 8534728
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of piperacillin during continuous ambulatory peritoneal dialysis].
Ryckelynck JP; Debruyne D; Hurault De Ligny B; Moulin M
Pathol Biol (Paris); 1988 May; 36(5):507-10. PubMed ID: 3043348
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.
Manley HJ; Elwell RJ; Bailie GR; Welch CL
Ann Pharmacother; 2004 Dec; 38(12):2035-40. PubMed ID: 15536141
[TBL] [Abstract][Full Text] [Related]
8. Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.
Pasadakis P; Thodis E; Eftimimiadou A; Panagoutsos S; Papazoglou D; Kaliengidou M; Kartali S; Vargemezis V
Adv Perit Dial; 1993; 9():206-10. PubMed ID: 8105925
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.
Montañés Pauls B; Almiñana MA; Casabó Alós VG
Eur J Pharm Sci; 2011 Jul; 43(4):212-6. PubMed ID: 21540106
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.
Zhu W; Fang X; Zheng J; Ke Y; He Q; Cui T; Chen B; Tian L
Ren Fail; 2023; 45(2):2285873. PubMed ID: 38044852
[TBL] [Abstract][Full Text] [Related]
11. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
12. Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.
Cardone KE; Grabe DW; Zasowski EJ; Lodise TP
Antimicrob Agents Chemother; 2014; 58(1):19-26. PubMed ID: 24126585
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study.
Chang MJ; Namgung H; Choi HD; Song YR; Kim SG; Oh JM; Shin WG
Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):504-9. PubMed ID: 22151828
[TBL] [Abstract][Full Text] [Related]
14. [Replacement of the peritoneal dialysis catheter in persistent peritonitis in continuous ambulatory peritoneal dialysis].
Marichal JF; Faller B; Mengus C; Wagner JD; Frey G
Nephrologie; 1985; 6(1):7-10. PubMed ID: 4000380
[TBL] [Abstract][Full Text] [Related]
15. [The latest trends in the treatment peritonitis of the patients on peritoneal dialysis].
Hájková B; Fixa P
Vnitr Lek; 2004 Aug; 50(8):619-23. PubMed ID: 15521206
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of peritonitis due to continuous ambulatory peritoneal dialysis using a single daily intraperitoneal dose of 1g cefotiam].
Ragnaud JM; Roche-Bezian MC; Marceau C; Demothes-Mainard F; Albin H; Prevost D; Wone C
Pathol Biol (Paris); 1986 May; 34(5):512-6. PubMed ID: 3534734
[TBL] [Abstract][Full Text] [Related]
17. Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients.
Peerapornratana S; Chariyavilaskul P; Kanjanabuch T; Praditpornsilpa K; Eiam-Ong S; Katavetin P
Perit Dial Int; 2017; 37(2):218-224. PubMed ID: 27738089
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of vancomycin in chronic renal failure patients in continuous ambulatory peritoneal dialysis (CAPD) after intra-abdominal administration].
Mounier M; Benevent D; Denis F
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):542-4. PubMed ID: 3911152
[TBL] [Abstract][Full Text] [Related]
19. Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis.
Gucek A; Bren AF; Hergouth V; Lindic J
Adv Perit Dial; 1997; 13():218-20. PubMed ID: 9360685
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
Demotes-Mainard F; Vinçon G; Ragnaud JM; Morlat P; Bannwarth B; Dangoumau J
J Clin Pharmacol; 1993 May; 33(5):475-9. PubMed ID: 8331207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
